Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (11): 1000-1007.doi: 10.35541/cjd.20230247
• Guidelines and Consensus • Previous Articles Next Articles
Chinese Society of Dermatology, China Dermatologist Association
Received:
2023-04-28
Revised:
2023-06-30
Online:
2023-11-15
Published:
2023-11-03
Contact:
Song Zhiqiang; Gao Xinghua
E-mail:drsongzq@hotmail.com; gaobarry@ hotmail.com
Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007.doi:10.35541/cjd.20230247
[1] | Bolognia JL, Schaffer JV, Cerroni L. Dermatology [M]. 4th ed. New York: Elsevier, 2018:208⁃227. |
[2] | Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018[J]. J Dermatol, 2019,46(12):1053⁃1101. doi: 10.1111/1346⁃8138.15090. |
[3] | Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis[J]. Nat Rev Dis Primers, 2018,4(1):1. doi: 10.1038/s41572⁃018⁃0001⁃z. |
[4] | 陈东宇, 杨晓雨, 王红心, 等. 中国居民1990⁃2019年皮肤及皮下疾病疾病负担变化趋势[J]. 中国公共卫生, 2022,38(5):529⁃533. doi: 10.11847/zgggws1137391. |
[5] | Dong WL, An J, Yu M, et al. The prevalence and year lived with disability of atopic dermatitis in China: findings from the global burden of disease study 2019[J]. World Allergy Organ J, 2021,14(11):100604. doi: 10.1016/j.waojou.2021.100604. |
[6] | Moon R, Kragh N, Troensegaard⁃Petersen N, et al. Flaring among atopic dermatitis patients ⁃ the perception of flaring burden between physicians and patients[J]. Value in health, 2017,20(9): A547. |
[7] | Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis[J]. J Allergy Clin Immunol, 2006,118(1):226⁃232. doi: 10.1016/j.jaci.2006.02.031. |
[8] | Gorritz M, Boytsov NN, Goldblum OM, et al. Inadequate response and treatment patterns in adults diagnosed with atopic dermatitis and treated with topical therapy[J]. J Dermatolog Treat, 2022,33(5):2510⁃2517. doi: 10.1080/09546634.2021.19 81813. |
[9] | Bruin⁃Weller M, Pink AE, Patrizi A, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study[J]. J Dermatolog Treat, 2021,32(2):164⁃173. doi: 10.1080/09546634.2020.186 6741. |
[10] | Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis[J]. J Dermatol, 2018,45(2):150⁃157. doi: 10.1111/1346⁃8138.14116. |
[11] | Armstrong AW, Huang A, Wang L, et al. Real⁃world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis[J/OL]. PLoS One, 2019,14(1):e0210517. doi: 10.1371/journal.pone.0210517. |
[12] | Wei W, Ghorayeb E, Andria M, et al. A real⁃world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate⁃to⁃severe Atopic Dermatitis (QUEST⁃AD): baseline treatment patterns and unmet needs assessment[J]. Ann Allergy Asthma Immunol, 2019,123(4):381⁃388. doi: 10.1016/j.anai.2019.07.008. |
[13] | Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis[J]. Ann Allergy Asthma Immunol, 2021,126(1):21⁃31. doi: 10.1016/j.anai.2020.08.016. |
[14] | Renert⁃Yuval Y, Guttman⁃Yassky E. New treatments for atopic dermatitis targeting beyond IL⁃4/IL⁃13 cytokines[J]. Ann Allergy Asthma Immunol, 2020,124(1):28⁃35. doi: 10.1016/j.anai.2019.10.005. |
[15] | Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease[J]. Nat Rev Drug Discov, 2022,21(1):21⁃40. doi: 10.1038/s41573⁃021⁃00266⁃6. |
[16] | De Bruin⁃Weller M, Biedermann T, Bissonnette R, et al. Treat⁃to⁃target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies[J]. Acta Derm Venereol, 2021,101(2):adv00402. doi: 10.2340/00015555⁃3751. |
[17] | 赵作涛, 高兴华. 中重度特应性皮炎系统药物达标治疗专家指导建议[J]. 中国皮肤性病学杂志, 2022,36(8):855⁃864. doi: 10.13735/j.cjdv.1001⁃7089.202205115. |
[18] | Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis[J].Acta Dermatovener(Stockholm), 1980,92(suppl):44⁃47. doi:10.2340/00015555924447. |
[19] | Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party′s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis[J]. Br J Dermatol, 1994,131(3):383⁃396. doi: 10.1111/j.1365⁃2133.1994.tb08530.x. |
[20] | Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis[J]. J Am Acad Dermatol, 2014,70(2):338⁃351. doi: 10.1016/j.jaad.2013.10.010. |
[21] | Liu P, Zhao Y, Mu ZL, et al. Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis[J]. Chin Med J (Engl), 2016,129(7):757⁃762. doi: 10.4103/0366⁃6999.178960. |
[22] | Cheng R, Zhang H, Zong W, et al. Development and validation of new diagnostic criteria for atopic dermatitis in children of China[J]. J Eur Acad Dermatol Venereol, 2020,34(3):542⁃548. doi: 10.1111/jdv.15979. |
[23] | Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting[J]. Allergy, 2012,67(9):1111⁃1117. doi: 10.1111/j.1398⁃9995.2012.02874.x. |
[24] | Leshem YA, Chalmers JR, Apfelbacher C, et al. Measuring atopic eczema symptoms in clinical practice: the first consensus statement from the harmonising outcome measures for eczema in clinical practice initiative[J]. J Am Acad Dermatol, 2020,82(5):1181⁃1186. doi: 10.1016/j.jaad.2019.12.055. |
[25] | Werfel T, Heratizadeh A, Aberer W, et al. Update "Systemic treatment of atopic dermatitis" of the S2k⁃guideline on atopic dermatitis[J]. J Dtsch Dermatol Ges, 2021,19(1):151⁃168. doi: 10.1111/ddg.14371. |
[26] | Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate⁃to⁃severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies[J]. J Allergy Clin Immunol Pract, 2017,5(6):1519⁃1531. doi: 10.1016/j.jaip.2017.08.005. |
[27] | Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate⁃to⁃severe atopic dermatitis[J]. Br J Dermatol, 2019,181(4):761⁃769. doi: 10.1111/bjd.17744. |
[28] | Silverberg JI, Lei D, Yousaf M, et al. What are the best endpoints for eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study[J]. Br J Dermatol, 2021,184(5):888⁃895. doi: 10.1111/bjd. 19457. |
[29] | Silverberg JI, Lei D, Yousaf M, et al. Measurement properties of the product of investigator′s global assessment and body surface area in children and adults with atopic dermatitis[J]. J Eur Acad Dermatol Venereol, 2021,35(1):180⁃187. doi: 10.1111/jdv.16846. |
[30] | Suh TP, Ramachandran D, Patel V, et al. Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): a practice⁃friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children[J]. J Am Acad Dermatol, 2020,82(5):1187⁃1194. doi: 10.1016/j.jaad.2020.01.023. |
[31] | Schram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference[J]. Allergy, 2012,67(1):99⁃106. doi: 10.1111/j.1398⁃9995.2011.02719.x. |
[32] | Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data[J]. Dermatology, 2015,230(1):27⁃33. doi: 10.1159/000365390. |
[33] | 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81⁃88. doi: 10.35541/cjd.20191000. |
[34] | Torres T, Gonçalo M, Paiva Lopes MJ, et al. Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients[J]. Drugs Context, 2021,10:2021⁃2029⁃5. doi: 10.7573/dic.2021⁃9⁃5. |
[35] | EuroGuiDerm Centre for Guideline Development. EuroGuiDerm Guideline on atopic eczema. Version 2.0[EB/OL].[2023⁃04⁃28]. https://guidelines.edf.one//guidelines/living⁃euroguiderm⁃guideline⁃for⁃the⁃systemic⁃treatment⁃of⁃atopic⁃eczema⁃2. |
[36] | Wollenberg A, Christen⁃Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children[J]. J Eur Acad Dermatol Venereol, 2020,34(12):2717⁃2744. doi: 10.1111/jdv.16892. |
[37] | 中国医师协会皮肤科医师分会自身免疫病专业委员会. 环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022,55(6):471⁃479. doi: 10.35541/cjd.20210434. |
[38] | 颜克香. 甲氨蝶呤在皮肤科的临床应用及注意事项[J]. 皮肤科学通报, 2021,38(4):320⁃326. |
[39] | 中国医师协会皮肤科医师分会自身免疫病专业委员会. 甲氨蝶呤治疗免疫相关性皮肤病专家共识[J]. 中华皮肤科杂志, 2021,54(5):382⁃390. doi: 10.35541/cjd.20200796. |
[40] | 张佩莲,叶建州.度普利尤单抗治疗特应性皮炎的不良反应与防治对策[J/OL].中国皮肤性病学杂志, 2022. (2022⁃10⁃19)[2023⁃04⁃28]. https://doi.org/10.13735/j.cjdv.1001⁃7089. 202207104. |
[41] | Marcant P, Balayé P, Merhi R, et al. Dupilumab⁃associated hypereosinophilia in patients treated for moderate⁃to⁃severe atopic dermatitis[J]. J Eur Acad Dermatol Venereol, 2021,35(6):e394⁃e396. doi: 10.1111/jdv.17177. |
[42] | Inokuchi⁃Sakata S, Ishiuji Y, Katsuta M, et al. Role of eosinophil relative count and neutrophil⁃to⁃lymphocyte ratio in the assessment of severity of atopic dermatitis[J]. Acta Derm Venereol, 2021,101(7):adv00491. doi: 10.2340/00015555⁃3838. |
[43] | 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中国老年保健医学研究会皮肤科分会. 系统Janus激酶抑制剂治疗特应性皮炎专家共识[J]. 实用皮肤病学杂志, 2022,15(3):129⁃135. doi: 10.11786/sypfbxzz.1674⁃1293.202 20301. |
[1] | Sun Xiaojie, Liu Yi. Anti-androgen drugs in the treatment of skin diseases [J]. Chinese Journal of Dermatology, 2023, 56(9): 882-885. |
[2] | Wang Yuqian, Qiao Jianjun, Fang Hong. Comparison of the latest Chinese and international guidelines/consensus on diagnosis and treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 885-888. |
[3] | Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802. |
[4] | Yuan Xingang, Ni Sili, Zhang Jian, Luo Xiaoyan, Wang Hua. Improving diagnosis and treatment of melanocytic nevi in children: an urgent need [J]. Chinese Journal of Dermatology, 2023, 56(8): 782-786. |
[5] | Zhong Jiemin, Shao Lei, Liang Yimin, Huang Qiongxiao, Xia Manqi, Liu Yumei. Comparative study on efficacy and safety of single microneedle radiofrequency versus photodynamic therapy in the treatment of inflammatory lesions of moderate to severe facial acne vulgaris [J]. Chinese Journal of Dermatology, 2023, 56(8): 751-755. |
[6] | Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723. |
[7] | Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition) [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625. |
[8] | Li Yue, Wu Jinyan, Yuan Ruoyue, Yang Quyang, Zhao Xiansheng, Zhu Ningwen. Cell therapy for hereditary epidermolysis bullosa [J]. Chinese Journal of Dermatology, 2023, 56(7): 698-702. |
[9] | Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566. |
[10] | Mi Shuhong, Yu Yanqin, Hao Jinqi, Li Wei, Zhang Yang, Jia Ximei, Huang Yuxian, Sun Huaiyu, Shi Jihai. Analysis of imaging characteristics of papulopustular rosacea by high-frequency ultrasound combined with color Doppler flow imaging [J]. Chinese Journal of Dermatology, 2023, 56(6): 540-544. |
[11] | Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558. |
[12] | Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China (2023)” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539. |
[13] | Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China (2023) [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488. |
[14] | Jin Shiying, Shi Jinjun, Gao Qi, Chen Mei, Dong Zhengbang, Yan Qiao, Li Jijian, Wang Fei. High-frequency ultrasonography-assisted evaluation of treatment outcomes of erysipelas: a prospective controlled study [J]. Chinese Journal of Dermatology, 2023, 56(5): 434-438. |
[15] | Ren Fenfen, Wang Peng, Zhang Jingzhan, Kang Xiaojing. Network pharmacology-based prediction of potential effective components of traditional Chinese medicine and their molecular mechanisms of action in the anti-angiogenic treatment of Kaposi′s sarcoma [J]. Chinese Journal of Dermatology, 2023, 56(5): 428-433. |
|